Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma

Rafael Fonseca, James Hoyer, Patricia Aguayo, Syed M. Jalal, Gregory J. Ahmann, S Vincent Rajkumar, Thomas Elmer Witzig, Martha Lacy, Angela Dispenzieri, Morie Gertz, Robert A. Kyle, Philip R. Greipp

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The most common chromosomal translocation in multiple myeloma (MM) is t(11;14)(q13;q32). Here, we describe the clinical characteristics of patients with MM who have this translocation. We have identified 24 patients at our institution who had t(11;14)(q13;q32) as determined by standard cytogenetic analysis (CC). Seven patients had the translocation detected at the time of original diagnosis and 17 at the time of relapse. Median survival in all patients after original diagnosis was 43 months; median survival after the translocation was detected was 11.9 months. Four patients had a clinical diagnosis of plasma cell leukemia. Most patients had an elevated β2-microglobulin (13/20 had > 4 μg/ml). The bone marrow (BM) labeling index (LI) of patients, at the time of translocation detection, was elevated in most (median 1.4%, 17/23 patients had BMLI ≥ 1%). Of the 24 patients, 19 (79%) died of disease progression and 5 (21%) were alive with disease at last follow-up. Lytic lesions, bone pain, or compression fractures eventually developed in all patients. Patients with MM who have t(11;14)(q13;q32) detected by standard cytogenetics seem to have an aggressive clinical course.

Original languageEnglish (US)
Pages (from-to)599-605
Number of pages7
JournalLeukemia and Lymphoma
Volume35
Issue number5-6
StatePublished - 1999

Fingerprint

Multiple Myeloma
Plasma Cell Leukemia
Compression Fractures
Genetic Translocation
Survival
Cytogenetic Analysis
Bone Fractures
Cytogenetics
Disease Progression
Bone Marrow
Recurrence
Pain

Keywords

  • Chromosomal aberrations
  • Leukemia
  • Multiple myeloma
  • Plasmacytic
  • Translocation t(11,14)(q13,q32)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. / Fonseca, Rafael; Hoyer, James; Aguayo, Patricia; Jalal, Syed M.; Ahmann, Gregory J.; Rajkumar, S Vincent; Witzig, Thomas Elmer; Lacy, Martha; Dispenzieri, Angela; Gertz, Morie; Kyle, Robert A.; Greipp, Philip R.

In: Leukemia and Lymphoma, Vol. 35, No. 5-6, 1999, p. 599-605.

Research output: Contribution to journalArticle

@article{8cef77ed43a8442aa3b7830437ff5825,
title = "Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma",
abstract = "The most common chromosomal translocation in multiple myeloma (MM) is t(11;14)(q13;q32). Here, we describe the clinical characteristics of patients with MM who have this translocation. We have identified 24 patients at our institution who had t(11;14)(q13;q32) as determined by standard cytogenetic analysis (CC). Seven patients had the translocation detected at the time of original diagnosis and 17 at the time of relapse. Median survival in all patients after original diagnosis was 43 months; median survival after the translocation was detected was 11.9 months. Four patients had a clinical diagnosis of plasma cell leukemia. Most patients had an elevated β2-microglobulin (13/20 had > 4 μg/ml). The bone marrow (BM) labeling index (LI) of patients, at the time of translocation detection, was elevated in most (median 1.4{\%}, 17/23 patients had BMLI ≥ 1{\%}). Of the 24 patients, 19 (79{\%}) died of disease progression and 5 (21{\%}) were alive with disease at last follow-up. Lytic lesions, bone pain, or compression fractures eventually developed in all patients. Patients with MM who have t(11;14)(q13;q32) detected by standard cytogenetics seem to have an aggressive clinical course.",
keywords = "Chromosomal aberrations, Leukemia, Multiple myeloma, Plasmacytic, Translocation t(11,14)(q13,q32)",
author = "Rafael Fonseca and James Hoyer and Patricia Aguayo and Jalal, {Syed M.} and Ahmann, {Gregory J.} and Rajkumar, {S Vincent} and Witzig, {Thomas Elmer} and Martha Lacy and Angela Dispenzieri and Morie Gertz and Kyle, {Robert A.} and Greipp, {Philip R.}",
year = "1999",
language = "English (US)",
volume = "35",
pages = "599--605",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma

AU - Fonseca, Rafael

AU - Hoyer, James

AU - Aguayo, Patricia

AU - Jalal, Syed M.

AU - Ahmann, Gregory J.

AU - Rajkumar, S Vincent

AU - Witzig, Thomas Elmer

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Gertz, Morie

AU - Kyle, Robert A.

AU - Greipp, Philip R.

PY - 1999

Y1 - 1999

N2 - The most common chromosomal translocation in multiple myeloma (MM) is t(11;14)(q13;q32). Here, we describe the clinical characteristics of patients with MM who have this translocation. We have identified 24 patients at our institution who had t(11;14)(q13;q32) as determined by standard cytogenetic analysis (CC). Seven patients had the translocation detected at the time of original diagnosis and 17 at the time of relapse. Median survival in all patients after original diagnosis was 43 months; median survival after the translocation was detected was 11.9 months. Four patients had a clinical diagnosis of plasma cell leukemia. Most patients had an elevated β2-microglobulin (13/20 had > 4 μg/ml). The bone marrow (BM) labeling index (LI) of patients, at the time of translocation detection, was elevated in most (median 1.4%, 17/23 patients had BMLI ≥ 1%). Of the 24 patients, 19 (79%) died of disease progression and 5 (21%) were alive with disease at last follow-up. Lytic lesions, bone pain, or compression fractures eventually developed in all patients. Patients with MM who have t(11;14)(q13;q32) detected by standard cytogenetics seem to have an aggressive clinical course.

AB - The most common chromosomal translocation in multiple myeloma (MM) is t(11;14)(q13;q32). Here, we describe the clinical characteristics of patients with MM who have this translocation. We have identified 24 patients at our institution who had t(11;14)(q13;q32) as determined by standard cytogenetic analysis (CC). Seven patients had the translocation detected at the time of original diagnosis and 17 at the time of relapse. Median survival in all patients after original diagnosis was 43 months; median survival after the translocation was detected was 11.9 months. Four patients had a clinical diagnosis of plasma cell leukemia. Most patients had an elevated β2-microglobulin (13/20 had > 4 μg/ml). The bone marrow (BM) labeling index (LI) of patients, at the time of translocation detection, was elevated in most (median 1.4%, 17/23 patients had BMLI ≥ 1%). Of the 24 patients, 19 (79%) died of disease progression and 5 (21%) were alive with disease at last follow-up. Lytic lesions, bone pain, or compression fractures eventually developed in all patients. Patients with MM who have t(11;14)(q13;q32) detected by standard cytogenetics seem to have an aggressive clinical course.

KW - Chromosomal aberrations

KW - Leukemia

KW - Multiple myeloma

KW - Plasmacytic

KW - Translocation t(11,14)(q13,q32)

UR - http://www.scopus.com/inward/record.url?scp=0033380205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033380205&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 599

EP - 605

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -